These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 23836955)
1. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Stewart MW Clin Ophthalmol; 2013; 7():1257-67. PubMed ID: 23836955 [TBL] [Abstract][Full Text] [Related]
2. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA; JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288 [TBL] [Abstract][Full Text] [Related]
8. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. Krick TW; Bressler NM Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861 [TBL] [Abstract][Full Text] [Related]
9. Corticosteroid use for diabetic macular edema: old fad or new trend? Stewart MW Curr Diab Rep; 2012 Aug; 12(4):364-75. PubMed ID: 22581206 [TBL] [Abstract][Full Text] [Related]
10. The clinical utility of aflibercept for diabetic macular edema. Stewart MW Diabetes Metab Syndr Obes; 2015; 8():473-82. PubMed ID: 26425104 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR; JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850 [TBL] [Abstract][Full Text] [Related]
12. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema. Mukkamala L; Bhagat N; Zarbin MA Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069 [TBL] [Abstract][Full Text] [Related]
13. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema. Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552 [TBL] [Abstract][Full Text] [Related]
14. The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan. Kitano S; Sakamoto T; Goto R; Fukushima A; Vataire AL; Hikichi Y J Med Econ; 2019 Mar; 22(3):254-265. PubMed ID: 30550375 [TBL] [Abstract][Full Text] [Related]
15. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940 [TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Virgili G; Parravano M; Menchini F; Brunetti M Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642 [TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516 [TBL] [Abstract][Full Text] [Related]